Merus’ (MRUS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Merus (NASDAQ:MRUS) in a report released on Friday, Benzinga reports. The firm currently has a $85.00 price target on the biotechnology company’s stock.

MRUS has been the subject of a number of other research reports. Lifesci Capital raised shares of Merus to a “strong-buy” rating in a research report on Monday, July 29th. Canaccord Genuity Group raised shares of Merus to a “strong-buy” rating in a research report on Thursday, July 25th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $67.00 price objective on shares of Merus in a research report on Thursday, July 25th. Needham & Company LLC cut their price target on shares of Merus from $92.00 to $85.00 and set a “buy” rating on the stock in a research note on Monday, August 5th. Finally, Guggenheim lifted their price target on shares of Merus from $93.00 to $111.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $86.70.

Merus Stock Performance

Shares of NASDAQ MRUS opened at $51.23 on Friday. The company has a 50 day simple moving average of $50.84 and a 200-day simple moving average of $51.44. Merus has a 1 year low of $22.01 and a 1 year high of $61.61.

Hedge Funds Weigh In On Merus

Hedge funds have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC purchased a new position in Merus during the first quarter valued at approximately $72,000. BNP Paribas Financial Markets lifted its stake in shares of Merus by 63.8% in the first quarter. BNP Paribas Financial Markets now owns 102,885 shares of the biotechnology company’s stock worth $4,633,000 after buying an additional 40,060 shares during the last quarter. Quantbot Technologies LP lifted its stake in shares of Merus by 160.7% in the first quarter. Quantbot Technologies LP now owns 7,300 shares of the biotechnology company’s stock worth $329,000 after buying an additional 4,500 shares during the last quarter. SG Americas Securities LLC acquired a new position in Merus during the 1st quarter valued at $108,000. Finally, Swiss National Bank raised its stake in Merus by 1.9% during the 1st quarter. Swiss National Bank now owns 74,054 shares of the biotechnology company’s stock valued at $3,335,000 after purchasing an additional 1,400 shares during the last quarter. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.